Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in PMR
2024-514210-12-00Phase 3Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Leflunomide with Placebo (2 arms). Primary endpoint: Time to first relapse at 12 months. Planned start Aug 2024; status: authorised.
02
Drugs
leflunomide
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2024-514210-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514210-12-00.